Zhi Tong Cai Jing·2025-11-20 01:48Core Viewpoint - Heptares Therapeutics-B (02142) shares rose over 6% in early trading, reaching HKD 14.68 with a trading volume of HKD 8.0214 million following the announcement of a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1]. Group 1 - Heptares Therapeutics-B's subsidiary, Nona Bio (Suzhou) Co., Ltd., has entered into a non-exclusive licensing agreement with Pfizer [1]. - The agreement allows Pfizer to gain global rights to Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1]. - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1]. Group 2 - Nona Bio will collaborate with Pfizer to utilize its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1].